Ann: AGM Presentation, page-57

First 57 Last

Share
Profile

Follow
resourceboom

871 Posts.

13

03/01/24

20:31

Post #: 71715307
Share

personally I prefer the smaller upfront for a larger royalty. It would be great if they get at least 1 more deal signed before interim results

Originally posted by vrs37: ↑

fair counter-argument.
"why do you think advanz happily made $10.7m upfront on this?"
can't comment on their business strategy, my research on them shows they seem to be a generics/biosimilar focus company with interest in going to rare diseases. no nephrology portfolio, means they will need to build nephrology network to commercialise this asset. as I said in earlier post, 10.7m AUD is loose change for a 500m USD business and according to the deal structure communicated by dimerx, advanz appears to have little or no exposure to the development risk? who know, maybe if the phase 2 dmx results had been stronger they'd have put up a much larger upfront?

"do they have better/updated data perhaps?"
I wouldn't know, do you know? not sure what new data that would be? the phase 2 would surely be too small and short to provide meaningful GFR data and if there was such important data then the company would have been expected to release to market already. the only other placebo-controlled results I'm aware of for this asset is their diabetes kidney disease study, but I read that flopped.

agree with your statistics comments. for transparency sake and best practice the p value and confidence intervals should have been communicated when the results from the phase 2 were released, but they weren't, at least not in the stuff I have seen. I would say that for any company.
looked at the other way, had the p value and confidence intervals been great, they'd have been promoted in highlights in all material releases.

Expand

DXB Price at posting: 24.0¢ Sentiment: None Disclosure: Held
5 Upvote

0 Great analysis

Reply

Top Stories

SS1

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

RCE

Recce's R327 found effective against E.coli during clinical trial

SVL

Silver Mines models five new calderas close to 396Moz Bowdens deposit

AVA

Ava Risk Group expands US presence with A$0.7M Substation Deal

Wealth Within weighs in on shock 4% inflation read – and stocks that could survive the gloom

There are more pages in this discussion • 21 more messages in this thread...

First 57 Last

Add DXB (ASX) to my watchlist

(20min delay)
Last 52.0¢		Change 0.010(1.96%)		Mkt cap ! $286.1M

Open	High	Low	Value	Volume
51.5¢	52.5¢	51.0¢	$905.3K	1.751M

Buyers (Bids)

No.	Vol.	Price($)
3	73479	52.0¢

Sellers (Offers)

Price($)	Vol.	No.
53.0¢	111148	4

View Market Depth

No.	Vol.	Price($)
3	35741	0.520
4	98490	0.515
12	508277	0.510
9	312276	0.505
17	418306	0.500

Price($)	Vol.	No.
0.525	23250	2
0.530	111148	4
0.535	59937	4
0.540	120000	2
0.545	24739	3

Last trade - 12.29pm 28/06/2024 (20 minute delay)

DXB (ASX) Chart

Ann: AGM Presentation, page-57

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

Recce's R327 found effective against E.coli during clinical trial

Silver Mines models five new calderas close to 396Moz Bowdens deposit

Ava Risk Group expands US presence with A$0.7M Substation Deal

Wealth Within weighs in on shock 4% inflation read – and stocks that could survive the gloom

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: AGM Presentation, page-57

Top Stories

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

Recce's R327 found effective against E.coli during clinical trial

Silver Mines models five new calderas close to 396Moz Bowdens deposit

Ava Risk Group expands US presence with A$0.7M Substation Deal

Wealth Within weighs in on shock 4% inflation read – and stocks that could survive the gloom

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News